Gapping down
In reaction to disappointing earnings/guidance: LULU -11%, KFY -8%, SWHC -3%, OXM -2.7%, COST -2.7%, KMI -2%, (DCF per share growing as businesses expected to generate slightly over $5 billion of cash in 2016; KMI expects to declare dividends of $.50 per share for 2016 and use excess cash to fund growth investments), FGP -1.6%, GTIM -0.6%
Other news: AEZS -26.8% (prices its underwritten public offering of common shares and warrants at $5.55/unit for net proceeds of ~$15 mln), ONTY -24.6% ( presents updated data from its ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of HER2-positive metastatic breast cancer ),CHRS -11.3% (updates on its CHS-1701 program, estimates that the follow-on study will cost less than $4 mln and entail about a quarter delay in projected BLA filing timing ), SPLS -1.5% (Staples and Office Depot (ODP) issue open letter after the Canadian Competition Bureau recently announced that it will seek to block Staples' acquisition of Grand & Toy), KITE -1.3% (announced $250 mln public offering of common stock), CONE -0.6% (CyrusOne announced that a subsidiary of Cincinnati Bell plans to sell 1.35 MLN of its shares of CyrusOne's common stock in an underwritten public offering)
Analyst comments: FFIV -2.4% (downgraded to Reduce from Neutral at Nomura), CME -0.9% (initiated with a Underperform at RBC Capital Mkts)
In reaction to disappointing earnings/guidance: LULU -11%, KFY -8%, SWHC -3%, OXM -2.7%, COST -2.7%, KMI -2%, (DCF per share growing as businesses expected to generate slightly over $5 billion of cash in 2016; KMI expects to declare dividends of $.50 per share for 2016 and use excess cash to fund growth investments), FGP -1.6%, GTIM -0.6%
Other news: AEZS -26.8% (prices its underwritten public offering of common shares and warrants at $5.55/unit for net proceeds of ~$15 mln), ONTY -24.6% ( presents updated data from its ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of HER2-positive metastatic breast cancer ),CHRS -11.3% (updates on its CHS-1701 program, estimates that the follow-on study will cost less than $4 mln and entail about a quarter delay in projected BLA filing timing ), SPLS -1.5% (Staples and Office Depot (ODP) issue open letter after the Canadian Competition Bureau recently announced that it will seek to block Staples' acquisition of Grand & Toy), KITE -1.3% (announced $250 mln public offering of common stock), CONE -0.6% (CyrusOne announced that a subsidiary of Cincinnati Bell plans to sell 1.35 MLN of its shares of CyrusOne's common stock in an underwritten public offering)
Analyst comments: FFIV -2.4% (downgraded to Reduce from Neutral at Nomura), CME -0.9% (initiated with a Underperform at RBC Capital Mkts)